- Home
- ARDX vs INVA Comparison
ARDX vs INVA Comparison
Compare ARDX & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARDX
- INVA
- Stock Information
- Founded
- ARDX 2007
- INVA 1996
- Country
- ARDX United States
- INVA United States
- Employees
- ARDX N/A
- INVA N/A
- Industry
- ARDX Biotechnology: Pharmaceutical Preparations
- INVA Biotechnology: Pharmaceutical Preparations
- Sector
- ARDX Health Care
- INVA Health Care
- Exchange
- ARDX Nasdaq
- INVA Nasdaq
- Market Cap
- ARDX 1.3B
- INVA N/A
- IPO Year
- ARDX 2014
- INVA 2004
- Fundamental
- Price
- ARDX $4.79
- INVA $17.94
- Analyst Decision
- ARDX Strong Buy
- INVA Buy
- Analyst Count
- ARDX 9
- INVA 1
- Target Price
- ARDX $10.61
- INVA $55.00
- AVG Volume (30 Days)
- ARDX 3.9M
- INVA 1.2M
- Earning Date
- ARDX 05-01-2025
- INVA 05-07-2025
- Dividend Yield
- ARDX N/A
- INVA N/A
- EPS Growth
- ARDX N/A
- INVA N/A
- EPS
- ARDX N/A
- INVA 0.36
- Revenue
- ARDX $333,615,000.00
- INVA $358,711,000.00
- Revenue This Year
- ARDX $14.26
- INVA N/A
- Revenue Next Year
- ARDX $32.49
- INVA $5.81
- P/E Ratio
- ARDX N/A
- INVA $49.55
- Revenue Growth
- ARDX 168.06
- INVA 15.54
- 52 Week Low
- ARDX $4.32
- INVA $14.33
- 52 Week High
- ARDX $9.33
- INVA $21.28
- Technical
- Relative Strength Index (RSI)
- ARDX 37.46
- INVA 56.45
- Support Level
- ARDX $4.68
- INVA $17.32
- Resistance Level
- ARDX $5.56
- INVA $18.34
- Average True Range (ATR)
- ARDX 0.25
- INVA 0.35
- MACD
- ARDX -0.05
- INVA 0.11
- Stochastic Oscillator
- ARDX 12.71
- INVA 69.92
About ARDX Ardelyx Inc.
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.